radiosurgery, as it is associated with fewer global cognitive side effects than WBRT and improved Mini-Mental State Examination scores posttreatment. 1, 4, 27, 29, 40 Additionally, brain metastases are particularly well suited for radiosurgery given that these lesions tend to have clear margins. 13 When used as a primary treatment for solitary metastasis, radiosurgery has been associated with local tumor control rates of 73%-94% and less morbidity than WBRT. 6, 7, 9, [12] [13] [14] 17, [19] [20] [21] 24, 29, 31, 36, 37 Radiosurgery has also been shown to reduce local tumor recurrence following grosstotal resection of a single brain metastasis. 14, 21, 30 Patients with systemic cancer and a single brain metastasis who undergo treatment with resection plus radiosurgery live longer and with a better quality of life than those treated with radiotherapy alone. 14, 21, 30 The success of SRS for patients with a solitary metastasis has induced practitioners to use radiosurgery for the treatment of multiple intracranial metastases as well; however, few studies have evaluated survival in this population. In the following study, we assessed survival in patients with single and multiple intracranial metastases who had undergone complete resection of dominant lesions and adjuvant radiosurgery to the surgical cavity and for synchronous lesions.
Methods
The Northwestern Memorial Hospital Institutional Review Board approved this study. We assessed the effect of SRS on metastatic brain tumors by reviewing a retrospectively acquired database of patients treated at the Northwestern Memorial Hospital Gamma Knife Radiosurgery Center. We examined the medical records of all consecutive patients with brain metastases treated via complete resection, as verified with postoperative MRI, between July 1998 and July 2006. Patients with MRI evidence (with Gd contrast administration) of residual or recurrent tumors on the first postresection day or those who had undergone initial subtotal resection (per the original operating neurosurgeon) were excluded from analysis.
Radiological and clinical follow-up consisted of clinic visits and MRI, which was performed within 3 months of radiosurgery and then at 3-month intervals, unless the patient's oncologist or neurosurgeon believed that more frequent imaging was necessary. All patients underwent follow-up at Northwestern Memorial Hospital Outpatient Neurosurgery Clinic. Key information was extracted from the electronic medical record: patient age, sex, primary tumor histology, surgery and SRS dates, death dates, cause of death, local progression, synchronous progression, meta chronous progression, systemic progression, and preoperative, intracranial, and metastatic burden.
The Kaplan-Meier method was used to calculate survival, and we performed time-to-event analysis. Time to local progression, synchronous lesion progression, meta chronous lesion development, and systemic progression as well as overall survival following resection and subsequent SRS were analyzed. These particular events were selected for evaluation based on a priori knowledge. Survival and progression rates were compared with previously published population data. Life tables were then generated for each type of progression, as were comparison Kaplan-Meier curves stratified by the categorical variables of number of intracranial lesions prior to surgery, tumor histology, sex, and age.
A Cox proportional-hazards regression model was also fitted with the number of lesions as the predictor and survival as the outcome controlling for disease severity, age, sex, and primary histology. When building this model, we examined several models and evaluated the impact of variable selection on maximum likelihood estimates. Scaled Schoenfeld residuals were used to test, that is, the proportional-hazards assumption. A nonzero slope was considered to be an indication of a violation of the proportional-hazards assumption. Data were analyzed using SAS version 9.2 (SAS Inc.), SPSS version 20 (IBM SPSS Inc.), and Excel 2011 (Microsoft Corp.). In all cases, an alpha level < 0.05 was considered statistically significant. Mean values were expressed with standard deviations, and median values were expressed with standard errors.
Results
One hundred fifty-one patients met the criteria for inclusion into the study cohort; however, 1 patient was excluded because of missing data in multiple fields, leaving 150 patients eligible for analysis. The median overall follow-up time was 17 months (IQR 6.65,46.2). There were 56 men and 94 women, with mean ages of 40.6 ± 12.9 years for men and 49.4 ± 12.6 years for women ( Table 1) . The mean number of intracranial lesions at the time of treatment was 2.5 ± 2.3, and the mean number of systemic metastases was significantly different between men (1.9 ± 0.9) and women (2.3 ± 0.9; p = 0.02). The overall mean number of systemic metastases was 2.5 ± 2.3.
The mean number of isocenters per lesion was 7.64 ± 6.66. The mean number of lesions treated with SRS was 2.5 ± 2.3. The mean prescription dose to the cavity margin was 17.8 ± 2.8 Gy. The prescription isodose ranged from 8 to 22 Gy (median 18 Gy).
Tumor characteristics were comparable between men and women. No discrepancy was noted in disease progression (local, synchronous, new, or systemic) or tumor histology between men and women, with the exception of a higher incidence of breast cancer as the primary histology in women. Overall mortality between men and women was comparable (78.6% vs 72.34%, respectively).
Median overall survival for our cohort was 13.2 ± 1.9 months and is presented as a Kaplan-Meier plot in Fig. 1 . One-and 2-year survivals were 52% and 33%, respectively. Median progression-free survival was 4.0 months (SE = 0.5 months) after SRS, and 17% of all patients were disease-free at 1-year posttreatment. All patients had some form of progression by the 3-year follow-up.
Survival analysis stratified by age, sex, tumor histology, and number of intracranial lesions at presentation was also performed. There was no significant association between age and survival ( Fig. 2A) . Women had significantly greater overall survival than males (16.3 vs 8.6 months, p = 0.037, Mantel-Cox log-rank test; Fig. 2B ). Primary histology was significantly correlated with survival ( Fig.  2C) . Patients with colon cancer had the shortest median overall survival (5.3 ± 1.8 months, p = 0.014, Mantel-Cox log-rank test). Patients with renal, skin (melanoma), lung, and breast cancer had respective median survival times of 8.6 ± 3.3, 12.9 ± 6.1, 15.5 ± 5.6, and 22.9 ± 6.2 months. There was no significant difference in survival between patients with a single lesion and those with multiple lesions (p = 0.319, Mantel-Cox log-rank test). Median survival for patients with 1 lesion was 16.1 ± 3.3; and for those with more than 2 lesions, it was 11.1 ± 2.0 months.
A time-to-event analysis was performed to determine the relationship between treatment and time to local, synchronous, metachronous, and systemic progression. The proportion of those with progression at the 1-and 2-year follow-up is presented in Table 2 . At the 1-year follow-up, 45% of patients progressed systemically, 38% had metachronous progression, 29% had synchronous progression, and 23% had local progression. All patients had progression in some form by the 3-year follow-up. The median time to progression was 3.0 ± 0.31 years for local lesions, 2.3 ± 0.22 years for synchronous lesions, 2.1 ± 0.23 years for metachronous lesions, and 1.8 ± 0.2 years for systemic lesions.
Last, a Cox proportional-hazards model was fit to evaluate the relationship between the number of intracranial lesions at the time of surgery and survival in patients who underwent surgery and Gamma Knife, controlling for the covariates of age, sex, and histology of primary cancer (Table 3 ). The proportional-hazards assumption was tested using Schoenfeld residuals, which showed that this assumption held. Patients with more than 2 intracranial lesions at presentation showed a trend toward an increase in mortality with an HR of 1.45 (95% CI 0.97-2.16), controlling for age, sex, and histology of primary tumor. In addition, those with breast cancer, lung cancer, and melanoma had a significant reduction in mortality (HR breast 0.49, 95% CI 0.24-0.98; HR lung 0.36, 95% CI 0.19-0.68; HR melanoma 0.46, 95% CI 0.20-1.0) as compared with those having other primary malignancies, controlling for age, sex, and time between diagnosis and surgery. Age was also a significant confounder (p = 0.04).
Discussion
In this study of patients with multiple intracranial metastases (mean 2.5 ± 2.3 lesions) treated with resection followed by SRS, we found a median overall survival of 13.2 ± 1.9 months, which represents an improvement over survival in previous studies evaluating radiotherapy alone for multiple metastases. 5, 34, 38, 42 Furthermore, the rate was comparable to those in previous reports of patients with a single metastasis treated via surgery and adjuvant SRS or WBRT. 8, 15, 18, 26, 32 In a recent review of literature on the use of SRS to the tumor bed following resection of a single intracranial metastasis, Gans et al. reviewed 14 studies comprising 629 patients who had undergone resection followed by SRS. The authors reported a median survival of 14 months with a 1-year local control rate of 85%. 8 These authors also reviewed reports on the use of WBRT following resection of a single metastatic focus and found a mean local control rate of 84%. We documented similar survival rates as well as local and synchronous control rates in our study, suggesting that surgery and adjuvant SRS provide intracranial disease control rates similar to those attained with surgery followed by WBRT. The main advantage of this treatment protocol is the avoidance of the long-term cognitive sequelae associated with WBRT while maintaining a similar efficacy for disease control. 1, 4, 29, 35, 40 Although the majority of patients in our study did eventually have intracranial tumor progression, it most commonly occurred between 1 and 2 years posttreatment, suggesting that surgery plus SRS provides adequate early control of intracranial disease. This is particularly relevant given that the median survival in our study was 13 months, suggesting that most patients were deceased prior to the time period in which intracranial progression was most likely to occur. This theory is supported by the fact that in the subset of patients for whom the cause of death was known, 79% died of extracranial disease. Given these findings, we believe that surgery followed by adjuvant SRS to the resection cavity and synchronous lesions represents an effective treatment protocol for patients with intracranial metastasis. Although WBRT may, in theory, suppress micrometastatic lesions outside the field of SRS, it has not been shown to improve mortality. 26, 42 In light of the significant neurocognitive sequelae associated with WBRT, we now favor SRS as adjuvant treatment for intracranial metastatic lesions. Our stratified analysis demonstrated a significant correlation between female sex and increased survival, which probably reflects the increased incidence of primary breast malignancy in females. Previous studies have reported excellent survival in breast cancer patients with intracranial metastasis, particularly those with a HER-2-positive phenotype. 23 In our study, primary breast histology was associated with a median survival of 22.9 months, significantly longer than for other primary histologies and an expected finding. Patients with colorectal cancer had the shortest overall median survival (5.3 months), which is consistent with a previous report by Matsunaga et al., who found a median survival of 6 months following Gamma Knife surgery for brain metastases from colorectal cancer. 22 In that series, the cause of death was systemic progression in 89% of cases, and 95% of patients had local intracranial control at the 6-month follow-up. As such, the authors proposed that Gamma Knife is an adequate treatment option for brain metastases from colorectal cancer because of both the short expected survival in these patients and the high-rates of early local control following radiosurgery.
There are several limitations to our study. First, the retrospective nature of our data limits our ability to establish causal relationships and introduces the potential for significant selection bias. Furthermore, the absence of a control group (that is, patients treated with surgery alone or with surgery plus adjuvant WBRT) is a significant limitation. Instead, we used historical published controls from previous studies of patients treated with WBRT. Future prospective randomized studies are necessary to validate our findings. Additionally, because of our limited sample size, our study may be too underpowered to detect differences between subgroups. Assuming a sample size of 151, a significance level of p = 0.05, a power = 0.8, a 2-sided test, an accrual interval of 1 month, a follow-up interval of 36 months, and a median time to failure of 11 months, this study is only powered to detect a minimal HR of 1.6. Therefore, it is quite possible that there is a difference in survival between these 2 groups but that the HR is less than 1.6. Another limitation is the absence of data on salvage therapy for intracranial recurrence; thus, it is unclear how local failure was managed in our series and what proportion of patients underwent repeat radiosurgery or WBRT. Finally, we did not include performance scores or functional outcomes in our study, as these data were unavailable for a majority of the patients. This is a significant limitation, as one of the primary reasons for using adjuvant radiosurgery is to avoid the long-term neurological sequelae associated with WBRT.
Despite these limitations, this study is, to our knowledge, the largest single-institution analysis of survival following resection and adjuvant SRS for patients with multiple intracranial metastases. Our findings suggest that this treatment protocol provides excellent rates of local and synchronous lesion control with acceptable overall survival. Future prospective randomized studies are needed to establish the efficacy of surgery and adjuvant SRS for multiple intracranial metastases relative to radiotherapy alone and surgery followed by WBRT. Of note, an ongoing phase III trial-Stereotactic Radiosurgery or Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases That Have Been Removed By Surgeryis poised to elucidate the safety and efficacy of adjuvant SRS compared with WBRT. We eagerly anticipate the results of this trial, set for completion by March 2014 and whose primary outcomes are neurocognitive markers as well as overall survival.
Conclusions
Stereotactic radiosurgery is effective in reducing local tumor recurrence following gross-total resection of a brain metastasis. Our results confirm that 1-year survival in patients with multiple intracranial metastases treated with resection followed by SRS is similar to established outcomes for patients with a single intracranial metastasis.
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